Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)

被引：7
|
作者：
George, D. J. [1 ]
Michaelson, M. D. [2 ]
Rosenberg, J. E. [3 ]
Redman, B. G. [4 ]
Hudes, G. R. [5 ]
Bukowski, R. M. [6 ]
Kim, S. T. [7 ]
Chen, I.
Wilding, G. [8 ]
Motzer, R. J. [9 ]
机构：
[1] Duke Univ, Ctr Med, Durham, NC 27706 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Philadelphia, PA USA
[6] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[7] Pfizer Inc, La Jolla, CA USA
[8] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA
[9] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71148-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4517
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [1] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [2] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [3] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
    Ballatore, Valentina
    Prati, Veronica
    Ruatta, Fiorella
    Galizia, Danilo
    Grignani, Giovanni
    Aglietta, Massimo
    Ortega, Cinzia
    ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
  • [4] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [5] Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Carducci, Michael Anthony
    Berger, Raanan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
  • [7] Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis
    Josephs, D. H.
    Hutson, T. E.
    Pickering, L. M.
    Larkin, J. M.
    Choueiri, T. K.
    Patel, T. V.
    Mcdermott, D. F.
    Powles, T.
    Harper, P. G.
    Chowdhury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results
    Srinivas, S.
    Roigas, J.
    Gillessen, S.
    Harmenberg, U.
    De Mulder, P. H.
    Fountzilas, G.
    Vogelzang, N.
    Peschel, C.
    Flodgren, P.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Renal safety of sunitinib treatment: A prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Rixe, O.
    Meric, J. B.
    Alexandre, J.
    Goldwasser, F.
    Izzedine, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 36 - 36
  • [10] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345